胃癌是消化系统最常见的恶性肿瘤，居我国恶性肿瘤病死率的第一位。由于大多数病人在确诊时已属进展期，传统的手术及放化疗整体预后不佳。分子靶向治疗是近年来肿瘤治疗领域中的研究热点，已在胃癌治疗中显示出高效、低毒等特点。目前分子靶向药物在胃癌治疗中的研究进展主要包括: （1）靶向于ErbB通道的胃癌靶向治疗；（2）以血管内皮生长因子及其受体为靶点的靶向治疗；（3）细胞周期调节剂与细胞凋亡促进剂；（4）针对上皮细胞黏附分子及胰岛素样生长因子?1受体的靶向治疗。

Molecular targeted therapy in the treatment of gastric cancer        LIU Kun,LI Guo-li.Nanjing General Hospital of Nanjing Military Command, Army of General Surgery Institute of PLA, Nanjing 210002,China
Corresponding  author：LI Guo-li，E-mail：drguoli@yahoo.com.cn
Abstract    Gastric cancer is the most common malignant tumor of the digestive system in our country, and its fatality rate is the first in the malignant tumor. Since most patients had been in a period of progress when they were treated ,traditional surgery, radiotherapy and chemotherapy got a poor prognosis. Targeted therapy was hot in the field of cancer treatment , with highly effective and low toxic in the stomach cancer treatment. Targeted drugs in the gastric cancer includes: （1）the  ErbB passage targeted therapy; (2)VEGF and receivers for the order;(3) cells cycle modifier and the apoptosis cells of the reactants； (4) targeted therapy by EpCAM and porcine IGF1R .